Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(N Engl J Med ;:-). In the Safety subsection of Results (page 8 in the version published online on December 11, 2019), the paragraph beginning Elevations in the ALT and AST levels should have ended, A single patient in the tucatinib-combination group met Hy's law criteria on the basis of ALT, 152 U per liter (4.8 times the upper limit of normal [ULN]); AST, 128 U per liter (3.6xULN); total bilirubin, 2.6 mg per deciliter (2.2xULN); and alkaline phosphatase (ALP), 165 U per liter (1.4xULN). This patient had an adaptive response, with recovery of laboratory values to baseline after dose modification of both tucatinib and . . .